The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
about
Towards tumor immunodiagnosticsTertiary Lymphoid Organs in Cancer TissuesCheckpoint Inhibitors and Their Application in Breast CancerTumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast CancerTumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune TargetingThe Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-AnalysisMacrophage migration inhibitory factor involvement in breast cancer (Review)Relevance of tumor-infiltrating lymphocytes in breast cancerCurrent Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerAdoptive T-cell therapy for cancer: The era of engineered T cellsCancer vaccinesRestoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionClinical significance of tumor-infiltrating lymphocytes in breast cancerValidation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationBreast cancer molecular subtypes: from TNBC to QNBCStrategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyondHigh definition infrared spectroscopic imaging for lymph node histopathologyTumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid ClassesTranslating neoadjuvant therapy into survival benefits: one size does not fit all.A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage ResponsHeterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategiesImmune DNA signature of T-cell infiltration in breast tumor exomes.Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancerPredictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinomaTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomesThe immune microenvironment of breast ductal carcinoma in situ.The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional studyTrogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patientsGene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancerGene-expression signature functional annotation of breast cancer tumours in function of ageDiscovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy
P2860
Q26738691-F8E9F351-EAC7-443A-AECF-C545A6C1E38EQ26742168-A5541813-214B-457B-8800-3DF4E181873FQ26745442-F11CF6FF-70BA-41C9-9B4B-A72E983EE345Q26745446-B207FB44-4E55-4157-B6E2-C088F00EA969Q26747792-BB5C5C21-B5BF-4823-82F1-5A5F56D846F6Q26748691-FE1D5164-4BDC-4458-9D73-B1E4C4C9943DQ26786136-923F881A-721F-43D4-98A9-DBB46659F485Q26795598-73307480-65DF-4FCF-BDD5-AEF581084A98Q26798074-7EFE7CD7-9317-40C5-BD32-32E424DDFCF1Q26800611-0A2F5BF8-F5B2-4249-87CB-5FB3171D528FQ27024438-5F7EC331-775C-4CB4-B29E-CE40C79F274DQ28067145-174D90CE-0675-43BC-B509-076669E8341CQ28070214-9E99390F-310A-4594-AC84-0255ECE1584EQ28075719-974F6A43-CFC5-4A4A-9D98-531926DCCC9BQ28076805-24F1832F-C9C6-4080-BD4C-F72F2B0A98BFQ28077815-51445119-58C1-4CC2-9D21-33360B613381Q28547806-E1726E4B-E3E1-46FC-8FFC-8921E1C521A2Q28554412-2B9C493B-FD31-4989-9512-D31CDE0C4BA5Q30251738-67638D78-4312-420B-910E-D120B06FA050Q30253017-69031F07-56DC-422D-9EEC-E8020E3850EDQ30275647-27ED83E2-E4B4-419D-84C4-F1BBBFE55A3FQ30377226-C04ECAAE-B338-4703-AE89-B4C996F3FC4EQ33576409-0F573E05-F83E-458E-A7FB-69D7BDCCB353Q33584033-C3F81545-4EC5-4FED-89B7-88F9CF1FABA4Q33584106-6FBCACDD-B315-46E6-A516-A8E48F22D644Q33654352-A0EE0099-3A61-4720-898F-0B517753A6F0Q33660069-53076126-CB98-4E79-A7D2-562E74FB8EFCQ33733725-2089428A-5386-48B3-AE78-27A21461EDB0Q33769821-3B1FA48F-B4CD-480C-8CD9-F08D72963A63Q33814856-980E64E1-8E3A-4940-ACA7-F5E825D26317Q33834968-E7D6F612-1098-4517-826F-61E370E953D2Q33888982-433E29B0-E04B-4370-B052-E239A7EAAD8DQ33915057-FFDB3146-B989-44F0-BAD5-5590DDE19FD3Q34567461-5B91DC86-31F8-4DE8-933A-7310A2CE925EQ35085679-C6AC39E3-DB4E-4BA7-9846-19D2E456DB2CQ35314135-5610A0DC-7709-467F-9FDC-4E71EB20949EQ35739745-0D99B702-5959-4F2F-B92A-775D2016C928Q35754593-C38A1A9D-52D4-4396-813B-6F56305A3D5BQ35849104-77E31B1D-2134-4F72-A865-85CFDE88A59FQ35857352-A51744AB-7E29-43F3-B3BC-B620578BDA69
P2860
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The evaluation of tumor-infilt ...... ional TILs Working Group 2014.
@en
The evaluation of tumor-infiltrating lymphocytes
@nl
type
label
The evaluation of tumor-infilt ...... ional TILs Working Group 2014.
@en
The evaluation of tumor-infiltrating lymphocytes
@nl
prefLabel
The evaluation of tumor-infilt ...... ional TILs Working Group 2014.
@en
The evaluation of tumor-infiltrating lymphocytes
@nl
P2093
P50
P356
P1433
P1476
The evaluation of tumor-infilt ...... tional TILs Working Group 2014
@en
P2093
A L Richardson
C Criscitiello
C Sotiriou
E A Thompson
F Klauschen
F L Baehner
F Penault-Llorca
P304
P356
10.1093/ANNONC/MDU450
P577
2014-09-11T00:00:00Z